Chief Executive Officer · Starling Oncology, Inc. (STLN)

Jeremy Castle

FY2024 is the first fiscal year CompBrief holds for Jeremy Castle as a named executive officer of Starling Oncology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$622,220

Salary $375,000Stock awards $41,792Bonus $100,950

3rd of 4 named executive officers at Starling Oncology by FY2024 total.

4 named officers on file for Starling Oncology, FY2024

Jeremy Castle’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Starling Oncology’s whole pay program stands against its peers

  • Starling Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STLN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 27, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jeremy Castle’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jeremy Castle compensation by year

Starling Oncology Summary Compensation Table · the one fiscal year held
In US dollars, as Starling Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$375,000
Bonus$100,950
Stock awards$41,792
Option awards$104,478
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$622,220

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Starling Oncology, Inc. DEF 14A filed March 27, 2025, accession 0001193125-25-064588, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Starling Oncology, Inc. filed document, accession 0001193125-25-064588. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU70,120$21,667—
RSU9,255$2,860—
Option23,137—$1.71
Option175,299—$2.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Starling Oncology, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2024 proxy (filed March 27, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-05-21Disposition to the issuer—5,636$2.67247,031
2025-03-31Grant or award—162,281$0.00252,667
2025-03-26Purchase—9,056$1.0490,386
2025-03-26Purchase derivative—4,528$0.134,528

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Starling Oncology’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Daniel VirnichChief Executive Officer$1,118,358
Mihir ShahChief Financial Officer$733,144
Jeremy Castle · this pageChief Executive Officer$622,220
Yale PodnosChief Medical Officer$610,332

The full Starling Oncology compensation record

free company brief

This page is one person within Starling Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Starling Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeremy Castle's compensation dossier · One-time report. No refunds.